Viral Infections Market to see 6.8% CAGR, hit $117.6B by 2021

PUNE, India, May 12, 2016 /PRNewswire/ --

Key drivers of viral infections market growth, globally, will be expanding treatment population, which has resulted from improved treatment options and global initiatives to improve access to treatment for many people living with chronic debilitating viral infections such as HIV. New market research titled "Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics" says the market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021.

Viruses are infectious particles comprising a nucleic acid core - consisting of either DNA or RNA - and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. Complete research report on Viral Infections Market 2021 with 4 market data tables and 75 figures, spread across 179 pages is available at http://www.rnrmarketresearch.com/global-viral-infections-market-to-2021-promising-new-competitors-and-expanding-treatment-population-to-offset-increased-uptake-of-generics-market-report.html .

Some 1,848 pipeline products are specifically in development for the treatment of viral infections, accounting for a sizeable proportion of the infectious diseases pipeline. Among these products, HIV has the most at an active stage of development, with 419, followed by influenza, Hepatitis C and Hepatitis B, with 333, 222 and 150 pipeline products, respectively. Such strong activity is indicative of a high degree of commercial interest in viral infections in general, and in these key indications in particular, which reflects the commercial success of currently marketed products such as Truvada, Atripla and Harvoni. However, it should be noted that many products in the viral infections pipeline are being developed for multiple indications, including infectious diseases attributable to non-viral micro-organisms.

The viral infections market is large and growing rapidly: How do epidemiology trends differ among the key indications? What therapeutic options exist for preventing and treating viral infections? Which products and companies dominate the market?

The pipeline is innovative and diverse: What is the proportion of early- to late-stage pipeline products? Which molecular targets are most prominent within the pipeline? How do the key indications differ in terms of molecule type?

Considerable market growth is anticipated throughout 2021: Which products will contribute to this growth most significantly? Will the current market leaders retain their dominance over the forecast period?

Deal values for licensing and co-development deals range considerably: How many strategic consolidations have been completed in the past decade? Which types of assets attract the largest deal values?

This 2016 viral infections market report allows its readers to:- Examine the current clinical and commercial landscape by considering disease pathogenesis, treatment options and key marketed products. Appreciate how the four key indications - HIV, HCV, HBV and influenza - differ in terms of epidemiology, symptoms and co-morbidities and complications. Identify trends and developments, in terms of molecule type and molecular target, within the overall viral infections pipeline, as well as for each of the four key indications. Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target. Recognize how the evolving treatment landscape will drive market growth to 2021 and understand the contributions that different products, molecular targets and companies will make to this growth. Understand how strategic consolidations have shaped the current pipeline and marketed product landscapes.

Order a copy of Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=542127 .

RnRMarketResearch.com has multiple newly published research reports on infectious diseases therapeutics and one of them is Schistosomiasis - Pipeline Review, H1 2016. This research provides comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects.  Read more at http://www.rnrmarketresearch.com/schistosomiasis-pipeline-review-h1-2016-market-report.html

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us: 
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed